Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446433 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
A Phase 2 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00446433 is a Phase 2 study that has completed, run by Celgene Corporation. The registered enrollment target is 90 participants.
The verdict
NCT00446433, a Phase 2 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease
Interventions
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446433
The ClinicalTrials.gov registry entry for NCT00446433 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-5013 is the first listed.
NCT00446433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00446433 about?
NCT00446433 is a clinical study titled "A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease". A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease
What is the current status of trial NCT00446433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2002-03. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00446433?
The interventions under investigation include: CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00446433?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.